New Research Highlights Bone Health Risks for Older Adults on GLP-1 Medications
Recent studies have revealed that GLP-1 medications, including Ozempic and Wegovy, which are commonly used for treating Type 2 diabetes and obesity, may pose additional risks for bone health, especially in older patients. Research indicates that elderly individuals starting on these medications have an 11% higher chance of experiencing fractures compared to those using other diabetes treatments.
Dr. Michal Kasher Meron, an endocrinologist and main author of the study, emphasized that although the percentage increase might seem minor, it is significant for this vulnerable age group. “Older age and Type 2 diabetes are both known risk factors for fragility fractures,” she noted, adding that this population needs particular focus when it comes to treatment.
Fragility fractures can occur from minor falls or everyday activities and often lead to severe consequences like loss of independence and increased mortality, as highlighted by Dr. Kasher Meron.
The research included over 46,000 participants aged 65 and older monitored over nearly three years. After adjustments for various factors, those using GLP-1 medications showed a modest increase in the risk of fractures.
In comparison to earlier studies focusing on younger populations, which didn’t indicate heightened fracture risks with older GLP-1 medications, these newer and more potent versions are now being prescribed more frequently to older adults. “In today’s context, the risk of fractures among older patients on these drugs needs careful consideration,” remarked Dr. Kasher Meron.
The study also pointed out that while GLP-1 users exhibited a 29% higher relative risk of osteoporosis over five years compared to non-users, there were slightly elevated cases of gout and osteomalacia—a condition marked by softened bones.
Researchers note that the exact reasons behind these associations remain unclear. Weight loss associated with GLP-1 use could potentially lead to less mechanical stress on bones, which, combined with dietary changes, might impact bone density negatively.
Dr. John Horneff, an orthopedic surgery specialist, compared the situation to astronauts in a zero-gravity environment, where bones lose density due to lack of pressure. “When bones aren’t used as much, they tend to weaken,” he explained.
Despite these concerns, experts stress that GLP-1 medications still offer important benefits, especially in managing blood sugar levels and aiding weight loss. They recommend regular bone density assessments for older patients before starting these medications and suggest a focus on nutrition and resistance training to help preserve muscle and bone mass during weight loss.
Novo Nordisk, the company behind these medications, assures that patient safety is a top priority and welcomes ongoing independent research to evaluate their products.
In conclusion, while GLP-1 drugs are effective for managing diabetes and aiding weight loss, older adults should be closely monitored for potential bone health issues. Ensuring a balanced diet and proper exercise can also play key roles in mitigating these risks.
